{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T18:03:59Z","timestamp":1795284239071,"version":"4.10.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2023,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In many situations, the therapeutic efficacy of CAR T cells is limited due to immune suppression and poor persistence. Immunostimulatory fusion protein (IFP) constructs have been advanced as a tool to convert suppressive signals into stimulation and thus promote the persistence of T cells, but no universal IFP design has been established so far. We now took advantage of a PD-1-CD28 IFP as a clinically relevant structure to define key determinants of IFP activity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We compared different PD-1-CD28 IFP variants in a human leukemia model to assess the impact of distinctive design choices on CAR T cell performance in vitro and a xenograft mouse model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We observed that IFP constructs that putatively exceed the extracellular length of PD-1 induce T-cell response without CAR target recognition, rendering them unsuitable for tumour-specific therapy. IFP variants with physiological PD-1 length ameliorated CAR T cell effector function and proliferation in response to PD-L1<jats:sup>+<\/jats:sup> tumour cells in vitro and prolonged survival in vivo. Transmembrane or extracellular CD28 domains were found to be replaceable by corresponding PD-1 domains for in vivo efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PD-1-CD28 IFP constructs must mimic the physiological interaction of PD-1 with PD-L1 to retain selectivity and mediate CAR-conditional therapeutic activity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-023-02332-9","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T02:01:38Z","timestamp":1688436098000},"page":"696-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy"],"prefix":"10.1038","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-032X","authenticated-orcid":false,"given":"Theo","family":"Lorenzini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7045-3898","authenticated-orcid":false,"given":"Bruno L.","family":"Cadilha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Obeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed-Reda","family":"Benmebarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4285-0380","authenticated-orcid":false,"given":"Florian","family":"M\u00e4rkl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanos","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thadd\u00e4us","family":"Strzalkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Briukhovetska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Jie","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayantan","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Majed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9044-3600","authenticated-orcid":false,"given":"Ruth","family":"Gr\u00fcnmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6581-6196","authenticated-orcid":false,"given":"Matthias","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Rausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8517-9681","authenticated-orcid":false,"given":"Tobias","family":"Feuchtinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Endres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5612-4673","authenticated-orcid":false,"given":"Sebastian","family":"Kobold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"2332_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"2332_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl J Med. 2018;378:439\u201348.","journal-title":"N. Engl J Med"},{"key":"2332_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl J Med. 2017;377:2531\u201344.","journal-title":"N. Engl J Med"},{"key":"2332_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl J Med. 2018;380:45\u201356.","journal-title":"N. Engl J Med"},{"key":"2332_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl J Med. 2020;382:1331\u201342.","journal-title":"N. Engl J Med"},{"key":"2332_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"2332_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl J Med. 2021;384:705\u201316.","journal-title":"N. Engl J Med"},{"key":"2332_CR8","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322\u201331.","journal-title":"Blood"},{"key":"2332_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl J Med. 2018;378:449\u201359.","journal-title":"N. Engl J Med"},{"key":"2332_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl J Med. 2014;371:1507\u201317.","journal-title":"N. Engl J Med"},{"key":"2332_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining \u2018T cell exhaustion\u2019. Nat Rev Immunol. 2019;19:665\u201374.","journal-title":"Nat Rev Immunol"},{"key":"2332_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2332_CR13","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N. Engl J Med. 2012;366:2443\u201354.","journal-title":"N. Engl J Med"},{"key":"2332_CR14","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood.2021012634","volume":"139","author":"EA Chong","year":"2022","unstructured":"Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022;139:1026\u201338.","journal-title":"Blood"},{"key":"2332_CR15","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","volume":"132","author":"EA Chong","year":"2018","unstructured":"Chong EA, Svoboda J, Dwivedy Nasta S, Landsburg DJ, Winchell N, Napier E, et al. Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-hodgkin lymphomas. Blood. 2018;132:4198.","journal-title":"Blood"},{"key":"2332_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","volume":"132","author":"AM Li","year":"2018","unstructured":"Li AM, Hucks GE, Dinofia AM, Seif AE, Teachey DT, Baniewicz D, et al. Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia. Blood. 2018;132:556.","journal-title":"Blood"},{"key":"2332_CR17","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu C, Chen Y-P, Du X-J, Liu J-Q, Huang C-L, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226.","journal-title":"BMJ"},{"key":"2332_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Ch\u00e1vez A, Keegan N, Khamashta MA, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Prim. 2020;6:38.","journal-title":"Nat Rev Dis Prim"},{"key":"2332_CR19","doi-asserted-by":"crossref","unstructured":"Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, et al. Impact of a new fusion receptor on PD-1\u2013mediated immunosuppression in adoptive T cell therapy. JNCI: J Natl Cancer Institute. 2015;107:djv146.","DOI":"10.1093\/jnci\/djv146"},{"key":"2332_CR20","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.4049\/jimmunol.1203085","volume":"191","author":"C Ankri","year":"2013","unstructured":"Ankri C, Shamalov K, Horovitz-Fried M, Mauer S, Cohen CJ. Human T cells engineered to express a programmed death 1\/28 costimulatory retargeting molecule display enhanced antitumor activity. J Immunol. 2013;191:4121\u20139.","journal-title":"J Immunol"},{"key":"2332_CR21","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","volume":"51","author":"ME Prosser","year":"2012","unstructured":"Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC. Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol Immunol. 2012;51:263\u201372.","journal-title":"Mol Immunol"},{"key":"2332_CR22","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76:1578\u201390.","journal-title":"Cancer Res"},{"key":"2332_CR23","doi-asserted-by":"crossref","unstructured":"Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Cadilha BL, et al. PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-hodgkin lymphoma. Front Immunol. 2018;9:1955.","DOI":"10.3389\/fimmu.2018.01955"},{"key":"2332_CR24","doi-asserted-by":"publisher","first-page":"1901434","DOI":"10.1080\/2162402X.2021.1901434","volume":"10","author":"C Chen","year":"2021","unstructured":"Chen C, Gu Y-M, Zhang F, Zhang Z-C, Zhang Y-T, He Y-D, et al. Construction of PD1\/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. OncoImmunology. 2021;10:1901434.","journal-title":"OncoImmunology"},{"key":"2332_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-021-00499-z","volume":"11","author":"F Blaeschke","year":"2021","unstructured":"Blaeschke F, Stenger D, Apfelbeck A, Cadilha BL, Benmebarek M-R, Mahdawi J, et al. Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins. Blood Cancer J. 2021;11:108.","journal-title":"Blood Cancer J"},{"key":"2332_CR26","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1182\/blood-2017-04-777052","volume":"130","author":"SK Oda","year":"2017","unstructured":"Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, et al. A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. Blood. 2017;130:2410\u20139.","journal-title":"Blood"},{"key":"2332_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/nprot.2007.132","volume":"2","author":"KL Heckman","year":"2007","unstructured":"Heckman KL, Pease LR. Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc. 2007;2:924\u201332.","journal-title":"Nat Protoc"},{"key":"2332_CR28","doi-asserted-by":"publisher","first-page":"eabi5781","DOI":"10.1126\/sciadv.abi5781","volume":"7","author":"BL Cadilha","year":"2021","unstructured":"Cadilha BL, Benmebarek M-R, Dorman K, Oner A, Lorenzini T, Obeck H, et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv. 2021;7:eabi5781.","journal-title":"Sci Adv"},{"key":"2332_CR29","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41551-021-00737-6","volume":"5","author":"S Lesch","year":"2021","unstructured":"Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, et al. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat Biomed Eng. 2021;5:1246\u201360.","journal-title":"Nat Biomed Eng"},{"key":"2332_CR30","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1038\/s41375-020-01109-w","volume":"35","author":"M-R Benmebarek","year":"2021","unstructured":"Benmebarek M-R, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, et al. A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia. 2021;35:2243\u201357.","journal-title":"Leukemia"},{"key":"2332_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cellimm.2007.02.014","volume":"244","author":"E Lazar-Molnar","year":"2006","unstructured":"Lazar-Molnar E, Almo SC, Nathenson SG. The interchain disulfide linkage is not a prerequisite but enhances CD28 costimulatory function. Cell Immunol. 2006;244:125\u20139.","journal-title":"Cell Immunol"},{"key":"2332_CR32","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.4049\/jimmunol.152.8.3848","volume":"152","author":"JR Young","year":"1994","unstructured":"Young JR, Davison TF, Tregaskes CA, Rennie MC, Vainio O. Monomeric homologue of mammalian CD28 is expressed on chicken T cells. J Immunol. 1994;152:3848\u201351.","journal-title":"J Immunol"},{"key":"2332_CR33","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"JN Kochenderfer","year":"2009","unstructured":"Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32:689\u2013702.","journal-title":"J Immunother"},{"key":"2332_CR34","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","volume":"23","author":"KM Zak","year":"2015","unstructured":"Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure. 2015;23:2341\u20138.","journal-title":"Structure"},{"key":"2332_CR35","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients. J Clin Investig. 2011;121:1822\u20136.","journal-title":"J Clin Investig"},{"key":"2332_CR36","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","volume":"167","author":"A Hombach","year":"2001","unstructured":"Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3\u03b6 signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28\/CD3\u03b6 signaling receptor molecule. J Immunol. 2001;167:6123\u201331.","journal-title":"J Immunol"},{"key":"2332_CR37","doi-asserted-by":"publisher","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","volume":"115","author":"AJ Davenport","year":"2018","unstructured":"Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci. 2018;115:E2068\u2013E76.","journal-title":"Proc Natl Acad Sci"},{"key":"2332_CR38","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.ymthe.2018.01.020","volume":"26","author":"W Xiong","year":"2018","unstructured":"Xiong W, Chen Y, Kang X, Chen Z, Zheng P, Hsu Y-H, et al. Immunological synapse predicts effectiveness of chimeric antigen receptor cells. Mol Ther. 2018;26:963\u201375.","journal-title":"Mol Ther"},{"key":"2332_CR39","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724\u201340.","journal-title":"Cell"},{"key":"2332_CR40","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36:847\u201356.","journal-title":"Nat Biotechnol"},{"key":"2332_CR41","doi-asserted-by":"publisher","first-page":"109625","DOI":"10.1016\/j.biopha.2019.109625","volume":"121","author":"E McGowan","year":"2020","unstructured":"McGowan E, Lin Q, Ma G, Yin H, Chen S, Lin Y. PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. Biomed Pharmacother. 2020;121:109625.","journal-title":"Biomed Pharmacother"},{"key":"2332_CR42","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Investig. 2016;126:3130\u201344.","journal-title":"J Clin Investig"},{"key":"2332_CR43","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"2332_CR44","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367:eaba7365.","journal-title":"Science"},{"key":"2332_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature24649","volume":"552","author":"T Wartewig","year":"2017","unstructured":"Wartewig T, Kurgyis Z, Keppler S, Pechloff K, Hameister E, \u00d6llinger R, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552:121\u20135.","journal-title":"Nature"},{"key":"2332_CR46","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","volume":"23","author":"J Ren","year":"2017","unstructured":"Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23:2255\u201366.","journal-title":"Clin Cancer Res"},{"key":"2332_CR47","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307\u201312.","journal-title":"Nature"},{"key":"2332_CR48","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","volume":"36","author":"CM Bollard","year":"2018","unstructured":"Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, et al. Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma. J Clin Oncol. 2018;36:1128\u201339.","journal-title":"J Clin Oncol"},{"key":"2332_CR49","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1182\/blood-2011-09-380519","volume":"119","author":"JH Shin","year":"2012","unstructured":"Shin JH, Park HB, Oh YM, Lim DP, Lee JE, Seo HH, et al. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. Blood. 2012;119:5678\u201387.","journal-title":"Blood"},{"key":"2332_CR50","doi-asserted-by":"crossref","unstructured":"Olgu\u00edn-Contreras LF, Mendler AN, Popowicz G, Hu B, Noessner E. Double strike approach for tumor attack: engineering T cells using a CD40L:CD28 chimeric co-stimulatory switch protein for enhanced tumor targeting in adoptive cell therapy. Front Immunol. 2021;12:750478.","DOI":"10.3389\/fimmu.2021.750478"},{"key":"2332_CR51","doi-asserted-by":"crossref","unstructured":"Oda SK, Anderson KG, Ravikumar P, Bonson P, Garcia NM, Jenkins CM, et al. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. J Exp Med. 2020;217:e20191166.","DOI":"10.1084\/jem.20191166"},{"key":"2332_CR52","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","volume":"27","author":"H Liu","year":"2021","unstructured":"Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, et al. CD19-specific CAR T cells that express a PD-1\/CD28 chimeric switch-receptor are effective in patients with PD-L1\u2013positive B-cell lymphoma. Clin Cancer Res. 2021;27:473\u201384.","journal-title":"Clin Cancer Res"},{"key":"2332_CR53","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1158\/0008-5472.CAN-16-1922","volume":"77","author":"R Schlenker","year":"2017","unstructured":"Schlenker R, Olgu\u00edn-Contreras LF, Leisegang M, Schnappinger J, Disovic A, R\u00fchland S, et al. Chimeric PD-1:28 receptor upgrades low-avidity T cells and restores effector function of tumor-infiltrating lymphocytes for adoptive cell therapy. Cancer Res. 2017;77:3577\u201390.","journal-title":"Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02332-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02332-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02332-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T11:03:05Z","timestamp":1691751785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-023-02332-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,9,7]]}},"alternative-id":["2332"],"URL":"https:\/\/doi.org\/10.1038\/s41416-023-02332-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"29 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Parts of this work have been performed for the doctoral thesis of TL. SE and SK are inventors of a patent application on one of the constructs presented herein. SE and SK have received research support from TCR2 Inc, Plectonic GmBH, Tabby Therapeutics, and Arcus Biosciences for work related to the present manuscript. SK has received honoraria from GSK, BMS, Novartis, Miltenyi Biotherapeutics, and TCR2 Inc. SE and SK have obtained licensing fees from TCR2 Inc and Carina Biotech. The authors declare that no other competing financial interests or conflicts of interest exist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Primary human T cells were isolated after written informed consent in accordance with the Declaration of Helsinki and approval by the Institutional Review Board of the Ludwig-Maximilians-Universit\u00e4t (Munich, Germany). All animal studies were approved by the local regulatory office on animal experimentation (Regierung von Oberbayern, Munich, Germany).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}